Early Clinical Study of JY306 Universal NK Cell Injection in the Treatment of Adult Relapsed or Refractory CD70+ Malignant Hematologic Tumors

EARLY_PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 15, 2025

Primary Completion Date

March 1, 2026

Study Completion Date

March 1, 2027

Conditions

Relapsed or Refractory Hematological Malignancies

Interventions

BIOLOGICAL

JY306 universal NK cell injection

"3+3 dose escalation trial"

All Listed Sponsors

lead

The First Affiliated Hospital with Nanjing Medical University

OTHER